JP6740340B2 - 免疫優性アデノウイルスエピトープに突然変異を有する腫瘍溶解性アデノウイルスおよび癌処置におけるそれらの使用 - Google Patents

免疫優性アデノウイルスエピトープに突然変異を有する腫瘍溶解性アデノウイルスおよび癌処置におけるそれらの使用 Download PDF

Info

Publication number
JP6740340B2
JP6740340B2 JP2018510008A JP2018510008A JP6740340B2 JP 6740340 B2 JP6740340 B2 JP 6740340B2 JP 2018510008 A JP2018510008 A JP 2018510008A JP 2018510008 A JP2018510008 A JP 2018510008A JP 6740340 B2 JP6740340 B2 JP 6740340B2
Authority
JP
Japan
Prior art keywords
adenovirus
epitope
cancer
tumor
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018510008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018519847A (ja
JP2018519847A5 (cg-RX-API-DMAC7.html
Inventor
ラモン、アレマニー
ラウル、ジル
ミリアム、バサン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VCN Biosciences SL
Original Assignee
VCN Biosciences SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VCN Biosciences SL filed Critical VCN Biosciences SL
Publication of JP2018519847A publication Critical patent/JP2018519847A/ja
Publication of JP2018519847A5 publication Critical patent/JP2018519847A5/ja
Application granted granted Critical
Publication of JP6740340B2 publication Critical patent/JP6740340B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2018510008A 2015-05-04 2016-05-04 免疫優性アデノウイルスエピトープに突然変異を有する腫瘍溶解性アデノウイルスおよび癌処置におけるそれらの使用 Active JP6740340B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562156748P 2015-05-04 2015-05-04
US62/156,748 2015-05-04
PCT/IB2016/052554 WO2016178167A1 (en) 2015-05-04 2016-05-04 Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment

Publications (3)

Publication Number Publication Date
JP2018519847A JP2018519847A (ja) 2018-07-26
JP2018519847A5 JP2018519847A5 (cg-RX-API-DMAC7.html) 2019-06-13
JP6740340B2 true JP6740340B2 (ja) 2020-08-12

Family

ID=55967340

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018510008A Active JP6740340B2 (ja) 2015-05-04 2016-05-04 免疫優性アデノウイルスエピトープに突然変異を有する腫瘍溶解性アデノウイルスおよび癌処置におけるそれらの使用

Country Status (7)

Country Link
US (1) US11000560B2 (cg-RX-API-DMAC7.html)
EP (1) EP3292142B1 (cg-RX-API-DMAC7.html)
JP (1) JP6740340B2 (cg-RX-API-DMAC7.html)
CN (1) CN107849111B (cg-RX-API-DMAC7.html)
AU (1) AU2016257196B2 (cg-RX-API-DMAC7.html)
ES (1) ES2987442T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016178167A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102272153B (zh) * 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
EP3092049A1 (en) 2014-01-08 2016-11-16 Flodesign Sonics Inc. Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
WO2017155935A1 (en) 2016-03-07 2017-09-14 The Johns Hopkins University Pharmaceutical agents targeting cancer stem cells
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
KR20190127655A (ko) 2016-10-19 2019-11-13 프로디자인 소닉스, 인크. 음향학에 의한 친화성 세포 추출
US20230242887A1 (en) * 2017-08-09 2023-08-03 Ohio State Innovation Foundation Oncolytic virus carrying e-cadherin and uses thereof
CN109576231B (zh) * 2017-09-28 2022-03-25 北京康万达医药科技有限公司 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
JP2021507561A (ja) 2017-12-14 2021-02-22 フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． 音響トランスデューサドライバ及びコントローラ
KR20210031852A (ko) * 2018-03-05 2021-03-23 클리니쿰 레히츠 데어 이자르 데어 테크니쉔 우니베르지테트 뮌헨 종양 세포 붕괴성 아데노바이러스와 cdk4/6 억제제의 조합물에 의한 종양의 치료
GB201804468D0 (en) 2018-03-21 2018-05-02 Valo Therapeutics Oy PeptiCRAd Cancer Therapy
WO2019191494A1 (en) 2018-03-28 2019-10-03 Epicentrx, Inc. Personalized cancer vaccines
CN110856751B (zh) 2018-08-24 2024-12-03 杭州康万达医药科技有限公司 包含核酸及tcr修饰的免疫细胞的治疗剂及其应用
CN110669740B (zh) * 2019-07-16 2021-10-08 伍泽堂 溶瘤病毒及其应用和治疗癌症的药物
CA3152965A1 (en) * 2019-09-05 2021-03-11 Klinikum Rechts Der Isar Der Technischen Universitat Munchen Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent
CN114292830B (zh) * 2021-12-31 2024-05-03 复旦大学 蛋白SaCas9的抗原表位及其在基因编辑中的应用
WO2024196669A2 (en) * 2023-03-17 2024-09-26 Walking Fish Therapeutics, Inc. Methods for in vivo editing of b cells

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5922315A (en) * 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
US7749492B2 (en) * 2001-01-05 2010-07-06 Nationwide Children's Hospital, Inc. AAV vectors and methods
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
ATE449105T1 (de) * 2004-01-23 2009-12-15 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
WO2005075514A2 (en) 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
WO2005107474A2 (en) 2004-04-30 2005-11-17 Introgen Therapeutics, Inc. Oncolytic adenovirus armed with therapeutic genes
WO2007015540A1 (ja) * 2005-08-03 2007-02-08 Medical And Biological Laboratories Co., Ltd. 細胞傷害性ｔ細胞エピトープペプチド及びその用途
WO2009117656A2 (en) * 2008-03-21 2009-09-24 Vectorlogics,Inc. Capsid-incorporated antigen for novel adenovirus vaccine
EP2379586B1 (en) 2008-12-22 2016-11-02 Targovax Oy Oncolytic adenoviral vectors and methods and uses related thereto
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
WO2011001276A1 (en) * 2009-06-30 2011-01-06 Philogen S.P.A. Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer
US20130029358A1 (en) * 2010-04-01 2013-01-31 Ludwig Institute For Cancer Research Ltd. Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof
WO2012024351A2 (en) * 2010-08-16 2012-02-23 Salk Institute For Biological Studies Adenoviral assembly method
CA2812096A1 (en) 2010-09-24 2012-03-29 Oncos Therapeutics Oy Adenoviral vectors and methods and uses related thereto
RU2598247C2 (ru) * 2010-11-25 2016-09-20 Имнейт Сарл Изменение иммуногенности антигена путем устранения эпитопов, узнаваемых nkt-клетками
SG10201606356YA (en) * 2012-02-02 2016-09-29 Univ Texas Adenoviruses expressing heterologous tumor-associated antigens
US9017672B2 (en) * 2012-05-11 2015-04-28 Immunicum Aktiebolag Hexon Tat-PTD modified adenovirus and uses thereof

Also Published As

Publication number Publication date
JP2018519847A (ja) 2018-07-26
AU2016257196A1 (en) 2017-11-30
CN107849111A (zh) 2018-03-27
EP3292142A1 (en) 2018-03-14
ES2987442T3 (es) 2024-11-14
US11000560B2 (en) 2021-05-11
CN107849111B (zh) 2022-02-22
EP3292142B1 (en) 2024-03-20
WO2016178167A1 (en) 2016-11-10
CA2985029A1 (en) 2016-11-10
AU2016257196B2 (en) 2021-11-25
US20180153946A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
JP6740340B2 (ja) 免疫優性アデノウイルスエピトープに突然変異を有する腫瘍溶解性アデノウイルスおよび癌処置におけるそれらの使用
KR102351555B1 (ko) Hpv 및 관련 질환용 면역 증강 치료 백신
CN106471125B (zh) 包括白蛋白结合部分的腺病毒
CN111630060B (zh) 用于在疾病的预防和/或治疗中使用的疫苗
US10617729B2 (en) Multitargeting onocolytic adenovirus, methods of use, and methods of making
US20150250837A1 (en) Oncolytic virus encoding pd-1 binding agents and uses of the same
EP3256140B1 (en) Compositions for ebola virus vaccination
CN103221544A (zh) 编码单克隆抗-ctla-4抗体的溶瘤腺病毒载体
CN118460616A (zh) 腺病毒载体
JP7417533B2 (ja) 改変腫瘍溶解性アデノウイルス
CN103930551A (zh) 猴腺病毒和杂合腺病毒载体
KR20180015113A (ko) 암을 치료하기 위한 치료 조성물 및 사용 방법
AU2017264901A1 (en) Combination prime: boost therapy
WO2015128313A1 (en) Rna viruses for immunovirotherapy
CN111479582A (zh) 免疫调节的复制高效的痘苗病毒株
CN108778326A (zh) 用于流感疫苗接种的方法和组合物
Bai et al. TNF-related apoptosis-inducing Ligand delivered by rNDV is a novel agent for cancer gene therapy
US20160002667A1 (en) Pseudomonas exotoxins for cancer treatment
DK2948157T3 (en) APPLICATION OF A RE-MODIFIED INFECTIOUS MEASURED VIRUS WITH IMPROVED PROAPOPTOTIC PROPERTIES (MV DELTAC VIRUS) FOR CANCER THERAPY
CA2985029C (en) Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment
JP2023547656A (ja) がんの腫瘍溶解性ウイルス免疫療法のための免疫チェックポイントを調節するｖｓｖ－ｎｄｖハイブリッドウイルス
HK40048152A (en) A vaccine for use in the prophylaxis and/or treatment of a disease
HK40012146A (zh) 表达异源肿瘤相关抗原的腺病毒
MXPA02003986A (en) Chimeric immunogenic compositions and nucleic acids encoding them

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190426

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200603

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200623

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200722

R150 Certificate of patent or registration of utility model

Ref document number: 6740340

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250